Dec 13, 2022 / 01:00AM GMT
Jan G.J. van de Winkel - Genmab A/S-Co-Founder - President & CEO
All right. So good evening, and welcome to all of you in person here in New Orleans, and of course, those of you who are participating via webcast. It's really wonderful to be here again in person this year. We have a busy agenda. So let's begin. So let's start with the next slide. I think one slide back. Yes. Genmab has a science-anchored and innovation-focused culture, and collaborations and partnerships have always been part of our DNA. And during tonight's presentation we will reference some of the products being developed under these strategic collaborations. And this slide actually acknowledges those relationships.
So let's move to Slide 3. We'll begin this evening with a review of the excellent progress we made this year as we progress towards our ambitious 2030 vision. And we are fortunate to have with us here Professor Torben Plesner, who will present the preliminary dose escalation data from the first-in-human trial of HexaBody-CD38, which was also presented at
Genmab A/S R&D Update and ASH Data Review Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers